SGLT2 inhibitors' India cardiac market penetration — the progressive adoption of SGLT2 inhibitors (empagliflozin and dapagliflozin) as heart failure therapy in India's urban cardiology practices and tertiary care hospitals — driven by the compelling efficacy evidence from DAPA-HF and EMPEROR-Reduced trials, India-specific guideline updates incorporating SGLT2 inhibitors, and the...